Доказательная кардиология

Клинические особенности и современные методы лечения сердечной недостаточности на фоне низкой и сохраненной фракции выброса: исследование CHARM (Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity programme)

Источники: Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362(9386):759-766.Granger C.B., McMurray J.J.V., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362(9386):772-776.McMurray J.J.V., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362(9386):767-771.Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003 Sep 6;362(9386):777-781.

Ключевые слова: